Systemic Oncolytic Cytokine HSV Therapy of Prostate Cancer
Abstract
We have made substantial progress toward the goals outlined in our grant application. In particular, we demonstrate the efficacy of systemically administered oncolytic viruses for the treatment prostate cancer in the transgenic TRAMP mouse model. We show that while intravenous administration of the NV1023 parental virus at 12 weeks of age (presence of prostate adenocarinoma) resulted in reduced tumor burden, the effects by the IL-12 expressing NV1042 virus were substantially more robust in reducing the frequency of primary tumor growth. Moreover, injection of this cytokine producing virus at 18 weeks of age (presence of metastatic disease)was more effective than NV1023 in reducing the occurrence of lung metastasis. Finally, persistence of tumor infectivity by NV1042 was established by detecting the LacZ-expressing NV1042 virus in the prostate at least 1 week after the final virus infection and also by identifying viral DNA by real-time PCR in both primary and metastatic tumors, but not in liver or blood at 2 weeks after final virus injection.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2006
- Accession Number
- ADA457031
Entities
People
- Susan Varghese
Organizations
- Massachusetts General Hospital